A ccording to a survey conducted by the American Association of Orthodontists, close to 5.9 million patients were treated for malocclusions in the United States during 2012. 1 There was a 20% increase in orthodontic patients from 2010 to 2012, with more adults seeking orthodontic treatment. 1 This points to a healthy trend for our specialty. Although a multitude of factors, such as improved technology have resulted in reduction of treatment duration, changes in insurance reimbursement policies, flexible spending accounts, and improved oral health have contributed to more people seeking orthodontic care, 1 and one should not discount the impact of innovative technologies such as the Invisalign system (Align Technology, San Jose, Calif) in contributing to this trend. With the growing popularity of the Invisalign system, it is expected that more patients would be inclined to use it rather than traditional braces for correcting their malocclusions. Whereas prior studies have examined treatment outcomes and patient satisfaction associated with the Invisalign system, there is a paucity of studies that have examined systemic adverse events associated with it. [2] [3] [4] [5] [6] Only a few studies have examined the cytotoxic effects of the Invisalign system 7, 8 ; these 2 studies were invitro investigations, and their effects cannot be extrapolated to humans. Consequently, there is a need for further research exploring potential side effects the Invisalign system on humans. To our knowledge, there are no published reports on adverse clinical events after the use of the Invisalign system. In this study, we attempted to address this gap in the literature. Our objectives were to examine adverse clinical events after the use of Invisalign and to provide an overview of actions taken by the manufacturer to address these events.
MATERIAL AND METHODS
This was a retrospective analysis of the Manufacturer and User Facility Device Experience (MAUDE) database of the United States Food and Drug Administration (FDA). 9 Since we used a publicly available database of the United States Department of Health and Human Services, as per the Office of Human Subjects Protection of the University of Iowa (protocol #201612726), the study did not meet the regulatory definition of human subjects research and did not require institutional review board approval, because it was limited to analysis of publicly available, deidentified data.
The MAUDE database houses all medical device reports (MDRs) reported to the FDA. Mandatory reporters to the MAUDE include manufacturers, importers, and deviceuser facilities, and voluntary reporters include health care professionals, patients, and consumers. 9 The MAUDE is a Web-based search engine (https://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfmaude/Search.cfm) that provides information on MDRs reported by both mandatory and voluntary reporters. Detailed information on the MAUDE database is available at https://www.fda. gov/MedicalDevices/DeviceRegulationandGuidance/Post marketRequirements/ReportingAdverseEvents/ucm127891. htm.
The MAUDE database is a passive surveillance system of MDRs. It can be searched by several variables including product problem, product class, event type, manufacturer, model number, report number, brand name, and product code. Only MDRs reported within the past 10 years are included in the MAUDE database. It is updated monthly. The information available from the MDRs typically includes brand name, model number, event date, event type, manufacturer narrative, event description, source type, reporter occupation, report date, adverse event report, device operator, device availability for evaluation, event location, device evaluation by manufacturer, type of device usage, and so on. Certain types of information in the event descriptions and manufacturer narratives are protected from public disclosure. In this study, we have used "XXX" to designate protected information.
The following search terms were used in the MAUDE database Web-based query system to identify MDRs pertaining to Invisalign systems: manufacturer, Align Technology and Align Technology Inc.; report date, November 1, 2006, to November 30, 2016; and no restrictions placed on any of the other queries.
Statistical analysis
After the search, data records were downloaded into an Excel spread sheet (Microsoft, Redmond, Wash) and imported into SPSS software (version 23.0; IBM, Armonk, NY).
Qualitative content analysis was performed on all event description narratives and manufacturer narratives. Two investigators (R.N. and M.K.L.) independently performed qualitative content analyses of 20 recent MDRs to identify recurring themes. These themes were discussed with the first author to identify adverse clinical events (based on event description and manufacturer narratives) to be reported in this study. After this, 2 authors (R.N and V.A.) independently reviewed all 173 MDRs and coded each clinical adverse event as a binomial variables ("yes" for occurrence and "no" for nonoccurrence). Simple descriptive statistics were used to report the clinical adverse events. A chi-square test was conducted to examine whether the proportion of adverse events that were deemed serious or life threatening was different across study years. Statistical analysis was conducted using the SPSS software.
RESULTS
During the observation period (November 1, 2006, to November 30, 2016), a total of 173 MDRs were reported in the MAUDE database. These included 138 MDRs reported by manufacturer (Align Technology) and 35 MDRs reported voluntarily by either patients, family members of patients, or health professionals (including dentists, physicians, and so on); 169 (97.7%) MDRs were designated as adverse event reports. Trends in the reporting of MDRs are given in Table I appeared to be an increasing trend toward more MDRs reported. In 45 (26%) MDRs, it was mentioned that the treating doctor thought that the event was serious or life threatening. The highest proportion of MDRs that reported a serious or life-threatening event was in 2014 (50%) followed by 2015 (46.7%). Overall, there were significant increases in the proportion of MDRs that were considered serious or life threatening from 2014 to 2016 when compared with earlier years (P 5 0.02). The frequencies of individual adverse clinical events are summarized in Table II . The most frequently reported adverse event was difficulty breathing (56 events) followed by sore throat (35 events), swollen throat (34 events), swollen tongue (31 events), hives and itchiness (31 events), anaphylaxis (30 events), swollen lips (27 events), feeling of throat closing/tight airway/airway obstruction/laryngospasm (24 events), chest pain (19 events), cough (19 events), nausea (18 events), difficulty swallowing (12 events), dry mouth (11 events), headaches (10 events), swelling of eyes (9 events), blisters or sores of lips (9 events), fatigue (8 events), burning/ tingling/sore tongue (7 events), blisters or ulcerations on tongue (6 events), and swelling of gums (5 events). Adverse events that were reported in fewer than 5 reports included lymph node enlargement, rashes on face or body, sinus tachycardia, palpitations, numbness of tongue, chest congestion, and joint pains. Several patients reported visiting emergency rooms, and several others reported being hospitalized.
The event description and the manufacturer narratives of the 10 most recent MDRs in which the treating doctor mentioned feeling that it was a "serious or lifethreatening event" are provided in Appendix 1, along with the source links. The following common themes were evident from the content analysis of the manufacturer's narratives of all 45 MDRs in which a serious or life-threatening event was mentioned.
1. No test methods were performed because the product performed according to specifications, and the device was used according to labeled indications. 2. No conclusive evidence was provided that supports or opposes that the Invisalign system aligners caused or contributed to the patient's symptoms. 3. Devices were not returned to the manufacturer.
Thirty-five MDRs were reported voluntarily by either patients, family members of patients, or health professionals (including dentists, physicians, and so on). Of these, 28 were reported by patients themselves. The narratives of event descriptions of the 2 most recent patient-reported MDRs are presented in Appendix 2. Content analysis of the event description of all patient-reported MDRs indicated that the patients believed that they experienced their reported symptoms after use of Invisalign trays; the symptoms minimized or disappeared after discontinuation of aligners. Patients would have liked to have more information on complications or adverse events associated with Invisalign systems and more information on product safety from the manufacturer.
DISCUSSION
We used the MAUDE database to examined adverse clinical events reported by the manufacturer (Align Techonology) and volunteers after use of Invisalign systems. While a prior study reported on adverse events during use of orthodontic aligners, none to our knowledge have documented adverse clinical events specifically while using the Invisalign system and the actions taken by manufacturer to address these adverse events. 10 Thsee results show that adverse events do occur with Invisalign. As with any medical device, providers and patients should be fully informed about all reported adverse events and any potential health risks with the Invisalign system. Our study showed that the most MDRs were reported in 2011. On November 17, 2010, the FDA issued a warning letter to Align Technology based on an inspection conducted in the summer of 2010 for failing to report serious adverse events associated with the Invisalign system. 11 Reports of adverse Several adverse clinical events-eg, difficulty breathing, swollen throat, anaphylactic reaction, swollen lips, laryngospasm, blisters-were reported in the MDRs. Invisalign aligners are composed of polyurethanes, and isocyanate is a critical component required for polyurethane synthesis. 13 Health effects of isocyanate have been well documented in the literature, including but not limited to increased risk of asthma and contact dermatitis. [14] [15] [16] [17] In an in-vitro cytotoxicity study, oral epithelial cells exposed to Invisalign aligners eluate showed increased cell death, compromised membrane integrity, and reduced cell-to-cell contact and mobility, which may be the mechanism for isocyanate allergy. 8 Forty-five MDRs reported a serious or lifethreatening event (per treating doctor). When we analyzed the manufacturer narratives of these MDRs, there was not a single instance when product testing was done. The manufacturer mentioned that "product performed in accordance to specifications and the device was used in accordance with labeled indications"; "no conclusive evidence has been provided that supports or opposes that the InvisalignÒ system aligners caused or contributed to the patients symptoms"; and "devices not returned to manufacturer." It appears to us that these reasons outlined by the manufacturer do not sufficiently address the serious concerns pertaining to lifethreatening events. A closeout letter issued by the FDA dated July 2015 indicates that the violations mentioned in the 2010 warning letter had been addressed. 18 However, our results show that most life-threatening events have occurred since 2014.
Analysis of the event description reports in MDRs filed by patients highlighted a few issues that providers and the manufacturer should pay attention to. Providers must clearly communicate to patients about potential unexpected serious life-threatening events as well as less serious complications associated with Invisalign systems so that patients can make an informed decision about using this product. Providers and their clinic personnel should become wary about how to handle these unexpected events. We believe that the adverse events are grossly underreported. We recommend that providers should provide information to the FDA via the MAUDE Web reporting system if they encounter incidents of adverse events after the start of the Invisalign system. We strongly urge the manufacturer to conduct product testing and take a more proactive approach to disseminate findings pertaining to complications and adverse events associated with Invisalign systems. As more "do-it-yourself" aligner companies set up shop, we are concerned that patients who use over-thecounter aligners without a health care provider supervising their treatment would be subjecting themselves to increased risks for adverse events, some of which could be life threatening.
This study is subject to several limitations, and the results and conclusions should be interpreted keeping these in perspective. The study is a retrospective qualitative content analysis of the MAUDE database MDRs. A true cause-and-effect relationship cannot be established in this study. With a qualitative approach, we cannot establish causality, account for confounders, or provide true prevalence and incidence estimates. External validity (generalizability) of findings is also questionable. We can identify, though, a problem that merits further investigation. Our study accomplishes this objective. We believe that our findings highlight areas (especially more product testings) that can be the subject of future well-designed prospective clinical studies. We used a qualitative content analysis approach to evaluate the event description reports and manufacturer narratives. 19 Our interpretations are subject to our personal biases even though we made every attempt to minimize these by having 2 researchers independently evaluate the MDRs. The MAUDE is a passive surveillance system, and its data are subject to limitations because of potential submission of incomplete, inaccurate, unverified, or biased data. 20 Information on frequency of use of the Invisalign systems is not available through the MAUDE; hence, the true incidence and prevalence rates of adverse events cannot be accurately quantified. The MDR data cannot be used in isolation to establish event rates. Based on the information available for the MAUDE, we cannot conclude that a true causal relationship exists between use of the Invisalign systems and the side effects, especially if the product has not been directly evaluated. Submission of an MDR either by the manufacturer or a volunteer reporter does not necessarily indicate that use of the product contributed to the event reported. 19 Despite these limitations, our findings are valuable, since
